Eli Gilboa

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. pmc DC-based cancer vaccines
    Eli Gilboa
    Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1550 NW 10th Avenue Medical Campus, Miami, FL 33136, USA
    J Clin Invest 117:1195-203. 2007
  2. pmc Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
    Alexey Berezhnoy
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA
    Mol Ther Nucleic Acids 1:e51. 2012
  3. ncbi request reprint Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay
    Eli Gilboa
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA
    Immunol Res 57:44-51. 2013
  4. doi request reprint Use of oligonucleotide aptamer ligands to modulate the function of immune receptors
    Eli Gilboa
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and the Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    Clin Cancer Res 19:1054-62. 2013
  5. pmc Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing
    Alexey Berezhnoy
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    Mol Ther 20:1242-50. 2012
  6. pmc Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
    Fernando Pastor
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami Miller School of Medicine Miami, Florida 33134, USA
    Nature 465:227-30. 2010
  7. pmc Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers
    Fernando Pastor
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
    Mol Ther 19:1878-86. 2011
  8. pmc Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    Jens Dannull
    Genitourinary Cancer Immunotherapy Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 115:3623-33. 2005
  9. ncbi request reprint Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts
    Jaewoo Lee
    Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:11156-63. 2005
  10. ncbi request reprint Cancer immunotherapy with mRNA-transfected dendritic cells
    Eli Gilboa
    Department of Surgery, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Rev 199:251-63. 2004

Collaborators

  • Johannes Vieweg
  • Daniel G Kavanagh
  • Paul R Hess
  • Giorgio Trinchieri
  • Smita Nair
  • M A Morse
  • Nina Bhardwaj
  • Simon M Barratt-Boyes
  • C Yee
  • J Schlom
  • H I Hurwitz
  • DUANE MITCHELL
  • Jens Dannull
  • Zhen Su
  • David Boczkowski
  • Alexey Berezhnoy
  • Fernando Pastor
  • Donna Yancey
  • Jaewoo Lee
  • Doris Coleman
  • Philipp Dahm
  • Martin Fassnacht
  • James O McNamara
  • Bruce A Sullenger
  • Despina Kolonias
  • Donna Niedzwiecki
  • Axel Heiser
  • Claudia M Dollins
  • Nada M Melhem
  • Peter E Fecci
  • Benjamin K Yang
  • Xinsheng Liao
  • Robin M Cisco
  • Yangbing Zhao
  • Brenda Faiola
  • C Andrew Stewart
  • Marcio Bajgelman
  • William Thiel
  • Dawn Seales
  • PALOMA GIANGRANDE
  • Randall Brenneman
  • Paloma H Giangrande
  • Juliana M Layzer
  • Xiang Dong Liu
  • Thomas J Cummings
  • Christopher A Learn
  • John H Sampson
  • Alison E Sweeney
  • Peter M Grossi
  • Xiuyu Cui
  • Darell D Bigner
  • Christian DeBeck
  • Nelson Chao
  • Aijing Zhang
  • Benjamin Yang
  • Caterina Milazzo
  • David Rizzieri
  • Sylvia Sichi
  • Yongqing Li
  • Yehia Daaka
  • Philip D Greenberg
  • Chiara Bonini
  • Zeinab Abdel-Wahab
  • Scott K Pruitt
  • Douglas S Tyler
  • Scott Pruitt
  • John Madden
  • Carolyn Doyle
  • Vandana Turaga
  • Costas D Lallas
  • John Higgins
  • Margaret A Maurice
  • Alon Z Weizer

Detail Information

Publications34

  1. pmc DC-based cancer vaccines
    Eli Gilboa
    Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, 1550 NW 10th Avenue Medical Campus, Miami, FL 33136, USA
    J Clin Invest 117:1195-203. 2007
    ....
  2. pmc Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
    Alexey Berezhnoy
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA
    Mol Ther Nucleic Acids 1:e51. 2012
    ..Molecular Therapy - Nucleic Acids (2012) 1, e51; doi:10.1038/mtna.2012.41; published online 16 October 2012...
  3. ncbi request reprint Expression of new antigens on tumor cells by inhibiting nonsense-mediated mRNA decay
    Eli Gilboa
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA
    Immunol Res 57:44-51. 2013
    ..The cell-free chemically synthesized oligonucleotide backbone of aptamer-siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use...
  4. doi request reprint Use of oligonucleotide aptamer ligands to modulate the function of immune receptors
    Eli Gilboa
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and the Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    Clin Cancer Res 19:1054-62. 2013
    ..The cell-free chemically synthesized ODN aptamers offer significant advantages over antibodies in terms of synthesis, cost, as well as conjugation chemistry needed to generate bispecific ligand fusions...
  5. pmc Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing
    Alexey Berezhnoy
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida 33136, USA
    Mol Ther 20:1242-50. 2012
    ..Systemic administration of the truncated aptamer was capable of inhibiting tumor growth in mice to an extent comparable to that of an anti- IL-10 receptor antibody...
  6. pmc Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
    Fernando Pastor
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami Miller School of Medicine Miami, Florida 33134, USA
    Nature 465:227-30. 2010
    ..The cell-free chemically synthesized oligonucleotide backbone of aptamer-siRNAs reduces the risk of immunogenicity and enhances the feasibility of generating reagents suitable for clinical use...
  7. pmc Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers
    Fernando Pastor
    Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute and Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
    Mol Ther 19:1878-86. 2011
    ..This study suggests that potentiating naturally occurring antitumor immunity via tumor-targeted costimulation could be an effective approach to elicit protective immunity to control tumor progression in cancer patients...
  8. pmc Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    Jens Dannull
    Genitourinary Cancer Immunotherapy Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 115:3623-33. 2005
    ..Our findings may have implications in the design of immune-based strategies that may incorporate the Treg depletion strategy to achieve potent antitumor immunity with therapeutic impact...
  9. ncbi request reprint Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts
    Jaewoo Lee
    Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:11156-63. 2005
    ..The study suggests that FAP, a product which is preferentially expressed in tumor-associated fibroblasts, could function as a tumor rejection antigen in a broad range of cancers...
  10. ncbi request reprint Cancer immunotherapy with mRNA-transfected dendritic cells
    Eli Gilboa
    Department of Surgery, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC 27710, USA
    Immunol Rev 199:251-63. 2004
    ..Immunization with mRNA-transfected DCs is a promising strategy to stimulate potent antitumor immunity and could serve as a foundation for developing effective treatments for cancer...
  11. ncbi request reprint Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity
    Smita Nair
    Department of Surgery, Duke Center for Translational Research and Medicine, Duke University Medical Center, Durham, NC, USA
    Cancer Res 67:371-80. 2007
    ....
  12. ncbi request reprint Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes
    Xinsheng Liao
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 N Fairview Avenue, Seattle, WA 98109, USA
    Mol Ther 9:757-64. 2004
    ..These studies provide compelling in vitro data supporting the evaluation of RNA-transfected mature DC in vaccination protocols as a means to overcome several obstacles to generating anti-tumor responses in vivo...
  13. ncbi request reprint Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy
    Martin Fassnacht
    Center for Translational Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:5566-71. 2005
    ..In this study, we describe a method to screen for human stromal products that have not triggered significant tolerance and could therefore serve as candidate antigens for cancer immunotherapy...
  14. ncbi request reprint Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells
    Zhen Su
    Cancer Immunotherapy Program, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 63:2127-33. 2003
    ..8 months. These data provide a scientific rationale for continued clinical investigation of this polyvalent vaccine strategy in the treatment of metastatic renal cell carcinoma and, potentially, other cancers...
  15. ncbi request reprint Synergy between tumor immunotherapy and antiangiogenic therapy
    Smita Nair
    Center for Genetic and Cellular Therapies, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Blood 102:964-71. 2003
    ..This study shows that coimmunizing mice against angiogenesis-associated and tumor-expressed antigens can deliver 2 compatible and synergistic cancer treatment modalities via a common treatment, namely immunization...
  16. ncbi request reprint Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:4294-305. 2006
    ..We therefore examined T(regs) in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct...
  17. pmc Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer
    Claudia M Dollins
    University Program in Genetics and Genomics, Duke University Medical Center, Durham, NC 27710, USA
    Chem Biol 15:675-82. 2008
    ....
  18. pmc Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef
    Daniel G Kavanagh
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, 149 13 St, Charlestown, MA 02129, USA
    Blood 107:1963-9. 2006
    ..Thus human dendritic cells transfected with mRNA encoding lysosome-targeted HIV antigen can expand a broad, polyclonal repertoire of antiviral T cells, offering a promising approach to HIV immunotherapy...
  19. ncbi request reprint Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag
    Nada M Melhem
    Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Eur J Immunol 37:2164-73. 2007
    ..These findings demonstrate that mRNA-transfected DC expressing SIV Ag derived from infected monkeys stimulate broad and relevant T cell responses, supporting this approach for therapeutic HIV vaccine development...
  20. ncbi request reprint Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen
    Paul R Hess
    Department of Microbiology, Pathology, and Parasitology, College of Veterinary Medicine, North Carolina State University, Raleigh, 27606, USA
    Cancer Immunol Immunother 55:672-83. 2006
    ..Nonetheless, limitations of such vaccines in overcoming tolerance to tumor/self Ag may mandate prior or simultaneous reconstitution of the autoreactive T cell repertoire for this form of immunization to be effective...
  21. ncbi request reprint Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer
    Zhen Su
    Genitourinary Cancer Immunotherapy Program, Division of Urology, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 174:3798-807. 2005
    ..Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers...
  22. pmc Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells
    Brenda Faiola
    Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA
    Immunology 105:47-55. 2002
    ..These observations provide convincing evidence that efficient CTL induction by DC in vivo requires concomitant presentation of class II epitopes for CD4(+) T-cell induction...
  23. pmc Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells
    Smita K Nair
    Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg 235:540-9. 2002
    ..To demonstrate the feasibility of inducing tumor antigen-specific immune responses in patients with metastatic cancer using total tumor RNA-loaded dendritic cells (DCs)...
  24. ncbi request reprint Emerging clinical applications of RNA
    Bruce A Sullenger
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Nature 418:252-8. 2002
    ..The first generation of the resulting RNA therapeutics are now being evaluated in clinical trials, raising significant interest in this emerging area of medical research...
  25. ncbi request reprint Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product
    Zhen Su
    Cancer Immunotherapy Program, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 62:5041-8. 2002
    ....
  26. ncbi request reprint The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..Autologous dendritic cells (DCs) loaded with tumor antigens are particularly potent at inducing tumor antigen-specific immune responses...
  27. ncbi request reprint Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
    ..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
  28. ncbi request reprint Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity
    Yangbing Zhao
    Department of Surgery, Box 2601, Duke University Medical Center, Durham, NC 27710, USA
    Blood 102:4137-42. 2003
    ..Transient inhibition of invariant chain expression represents a simple and general method to enhance the stimulation of CD4+ T-cell responses from endogenous antigens...
  29. ncbi request reprint Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation
    Smita Nair
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 171:6275-82. 2003
    ..This study shows that in situ maturation offers a simpler and potentially superior method to generate potent immunostimulatory DC for clinical immunotherapy...
  30. ncbi request reprint The promise of cancer vaccines
    Eli Gilboa
    The Center for Cellular and Genetic Therapies, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Rev Cancer 4:401-11. 2004
  31. ncbi request reprint Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4
    Robin M Cisco
    Department of Surgery, Duke University and Durham Veterans Affairs Medical Centers, Durham, NC 27710, USA
    J Immunol 172:7162-8. 2004
    ....
  32. ncbi request reprint Knocking the SOCS1 off dendritic cells
    Eli Gilboa
    Nat Biotechnol 22:1521-2. 2004
  33. ncbi request reprint Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand
    Jens Dannull
    Division of Urology, Duke University Medical Center, Durham, NC 27710, USA
    Blood 105:3206-13. 2005
    ....
  34. pmc Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
    Axel Heiser
    Cancer Immunotherapy Program, Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 109:409-17. 2002
    ....

Research Grants27

  1. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2003
    ..The studies described in this application will set the stage for clinical trials using immunological end points to determine whether "in situ maturation" generates potent APC to stimulate T cell immunity in cancer patients. ..
  2. CANCER VACCINATION AGAINST TELOMERASE
    Eli Gilboa; Fiscal Year: 2001
    ..The studies proposed in this application will provide the foundations for this ambitious goal. ..
  3. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2006
    ..The studies described in this application will set the stage for clinical trials using immunological end points to determine whether "in situ maturation" generates potent APC to stimulate T cell immunity in cancer patients. ..
  4. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2006
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  5. Development of Oligonucleotide-based CTLA-4 Inhibitors
    Eli Gilboa; Fiscal Year: 2006
    ..Successful completion of the proposed studies will set the stage for clinical trials to test the therapeutic benefit of using CTLA-4 binding aptamers in conjunction with immunotherapy in cancer patients. ..
  6. Development of Oligonucleotide-based CTLA-4 Inhibitors
    Eli Gilboa; Fiscal Year: 2006
    ..Successful completion of the proposed studies will set the stage for clinical trials to test the therapeutic benefit of using CTLA-4 binding aptamers in conjunction with immunotherapy in cancer patients. ..
  7. TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES
    Eli Gilboa; Fiscal Year: 2003
    ..The studies proposed in this application will set the stage for the development of improved generation of RNA transfected DC vaccines. ..
  8. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2006
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  9. TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES
    Eli Gilboa; Fiscal Year: 2002
    ..The studies proposed in this application will set the stage for the development of improved generation of RNA transfected DC vaccines. ..
  10. CANCER VACCINATION AGAINST TELOMERASE
    Eli Gilboa; Fiscal Year: 2002
    ..The studies proposed in this application will provide the foundations for this ambitious goal. ..
  11. TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES
    Eli Gilboa; Fiscal Year: 2001
    ..The studies proposed in this application will set the stage for the development of improved generation of RNA transfected DC vaccines. ..
  12. Development of Oligonucleotide-based CTLA-4 Inhibitors
    Eli Gilboa; Fiscal Year: 2007
    ..Successful completion of the proposed studies will set the stage for clinical trials to test the therapeutic benefit of using CTLA-4 binding aptamers in conjunction with immunotherapy in cancer patients. ..
  13. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2007
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  14. TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES
    Eli Gilboa; Fiscal Year: 2000
    ..The studies proposed in this application will set the stage for the development of improved generation of RNA transfected DC vaccines. ..
  15. TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES
    Eli Gilboa; Fiscal Year: 2004
    ..The studies proposed in this application will set the stage for the development of improved generation of RNA transfected DC vaccines. ..
  16. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2003
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  17. CANCER VACCINATION AGAINST TELOMERASE
    Eli Gilboa; Fiscal Year: 2004
    ..The studies proposed in this application will provide the foundations for this ambitious goal. ..
  18. Development of Oligonucleotide-based CTLA-4 Inhibitors
    Eli Gilboa; Fiscal Year: 2004
    ..Successful completion of the proposed studies will set the stage for clinical trials to test the therapeutic benefit of using CTLA-4 binding aptamers in conjunction with immunotherapy in cancer patients. ..
  19. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2004
    ..The studies described in this application will set the stage for clinical trials using immunological end points to determine whether "in situ maturation" generates potent APC to stimulate T cell immunity in cancer patients. ..
  20. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2004
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  21. Cancer Immunotherapy Targeting Endothelial Antigens
    Eli Gilboa; Fiscal Year: 2005
    ..The existence of the required expertise, infrastructure and the clinical immunotherapy programs at Duke will facilitate and expedite the clinical translation of these proof-of concept murine studies. ..
  22. Development of Oligonucleotide-based CTLA-4 Inhibitors
    Eli Gilboa; Fiscal Year: 2005
    ..Successful completion of the proposed studies will set the stage for clinical trials to test the therapeutic benefit of using CTLA-4 binding aptamers in conjunction with immunotherapy in cancer patients. ..
  23. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2006
    ..The studies described in this application will set the stage for clinical trials using immunological end points to determine whether "in situ maturation" generates potent APC to stimulate T cell immunity in cancer patients. ..
  24. Cancer Immunotherapy w/In-Situ Maturated Dendritic cells
    Eli Gilboa; Fiscal Year: 2005
    ..The studies described in this application will set the stage for clinical trials using immunological end points to determine whether "in situ maturation" generates potent APC to stimulate T cell immunity in cancer patients. ..
  25. CANCER VACCINATION AGAINST TELOMERASE
    Eli Gilboa; Fiscal Year: 2005
    ..The studies proposed in this application will provide the foundations for this ambitious goal. ..
  26. CANCER VACCINATION AGAINST TELOMERASE
    Eli Gilboa; Fiscal Year: 2003
    ..The studies proposed in this application will provide the foundations for this ambitious goal. ..